CHINESE JOURNAL OF MEDICINAL GUIDE >

2026 , Vol. 28 >Issue 5: 548 - 548-557

DOI: https://doi.org/10.1009-0959.2026.050019

Pharmacodynamics and Safety Evaluation of Shengxian Decoction in Treating Chronic Heart Failure

  • Chao Wang ,
  • Tao Pang ,
  • Liyuan Yang ,
  • Xia Tao ,
  • Feng Zhang ,
  • Wansheng Chen
Expand
  • 1.Institute of Chinese Materia Medica， Shanghai University of Traditional Chinese Medicine， Shanghai 201203， China；
    2.Department of Pharmacy， the Second Affiliated Hospital of Naval Medical University， Shanghai 200003， China；
    3.Tongji University School of Medicine Affiliated Shanghai Baoshan District Songnan Town Community Health Center，
    Shanghai 200441， China；
    4.School of Pharmacy， Shanghai University of Traditional Chinese Medicine， Shanghai 201203， China

Received date: 2025-12-10

  Revised date: 2026-02-13

  Accepted date: 2026-04-20

  Online published: 2026-06-29

Fold

Abstract

Objective： To determine the efficacy of Shengxian decoction on chronic heart failure （CHF） and assess its safety.Methods： For efficacy evaluation， the rat model of CHF following acute myocardial ischemia was established by ligating the left anterior descending coronary artery. The rats were divided into five groups （n=7 per group）： sham group， model group， Shengxian decoction low-dose group （4 g·kg-1）， Shengxian decoction high-dose group （16 g·kg-1）， and positive drug group. The corresponding medicine or saline were administered via gavage for 35 consecutive days. The rat body weight was recorded， and echocardiographic， serum biochemical， and histopathological assessments were performed at the end of the experiment. For the safety evaluation， a one-month repeated-dose study was conducted in rats. The rats were divided into four groups （n=30 per group， half male and half female）： control group， Shengxian decoction low-dose group （8 g·kg-1）， Shengxian decoction medium-dose group （16 g·kg-1）， and Shengxian decoction high-dose group （32 g·kg-1）. Medicine or purified water （control） were administered daily via gavage for 28 days. The general physiological observations were recorded. At the end of the dosing period， the indicators such as hematology， coagulation， serum biochemistry， urinalysis， and organ coefficients of rats were detected. Histopathological examination was performed on key organs of rats in the high-dose group.Results： The pharmacodynamic study demonstrated that Shengxian decoction significantly ameliorated body weight loss， increased left ventricular ejection fraction （EF） and left ventricular fractional shortening （FS）， reduced serum levels of creatine kinase （CK） and lactate dehydrogenase （LDH）， and reduced pathological lesions in CHF rats. The toxicology study indicated that Shengxian decoction had no toxicologically relevant effects on body weight， food consumption， hematology， coagulation， serum biochemistry， urinalysis， or histopathology up to the highest tested dose. The no-observed-adverse-effect level （NOAEL） was determined to be >32 g （crude drug）/kg， which is equivalent to 50 times of the clinical human dose.Conclusion： Shengxian decoction exerts a significant protective effect against CHF induced by left anterior descending coronary artery ligation in rats and demonstrates a favorable safety profile.


Key words：  ; Shengxian decoction； ; Chronic heart failure ; （CHF）； ; Pharmacodynamics； ; Safety evaluation

Cite this article

Chao Wang , Tao Pang , Liyuan Yang , Xia Tao , Feng Zhang , Wansheng Chen .

Pharmacodynamics and Safety Evaluation of Shengxian Decoction in Treating Chronic Heart Failure

[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2026 , 28(5) : 548 -548-557 . DOI: 10.1009-0959.2026.050019

References

    ［1］ Amdani S， Conway J， George K， et al. Evaluation and management of chronic heart failure in children and adolescents with congenital heart disease： a scientific statement from the American heart association［J］.Circulation， 2024，150（2）：e33-e50.

         ［2］  Triposkiadis F， Xanthopoulos A， Parissis J， et al. Pathogenesis of chronic heart failure： cardiovascular aging， risk factors， comorbidities， and disease modifiers［J］.Heart Fail Rev， 2022，27（1）：337-344.

         ［3］  薄慧赢，侯平.慢性心力衰竭的中西医发病机制及现代治疗药物的研究进展［J］.实用中医内科杂志，2025，39（2）：1-4.

         ［4］  Guaricci AI， Sturdà F， Russo R， et al. Assessment and management of heart failure in patients with chronic kidney disease［J］.Heart Fail Rev， 2024，29（2）：379-394.

         ［5］  Heidenreich PA， Bozkurt B， Aguilar D， et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure： executive summary： a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines［J］.Circulation， 2022，145（18）：e876-e894.

         ［6］  杨过，张艳，袁子阳.中医经典名方治疗慢性心力衰竭的临床及机制研究进展［J］.中国实验方剂学杂志，2026，32（9）：256-265.

         ［7］  曲阳，方媛，林春盛.经典名方升陷汤应用研究进展［J］.航空航天医学杂志，2025，36（4）：433-435.

         ［8］  朱慧明，郝雨欣，程佳洁，等.古代经典名方升陷汤治疗心血管疾病的作用机制和物质基准指标成分研究［J］.中国医药导刊，2022，24（12）：1222-1229.

         ［9］  周浩明，乐世俊，刘文娟，等.经典名方升陷汤的研究进展及质量标志物的预测分析［J］.中国现代中药，2024，26（3）：550-565.

         ［10］ 马玉龙，史鑫鑫，陈晓喆，等.基于大气下陷理论探讨升陷汤在慢性心力衰竭中的应用［J］.陕西中医，2021，42（8）：1100-1102，1107.

         ［11］ 唐震，张明雪.中医药治疗慢性心力衰竭临床研究进展［J］.实用中医内科杂志，2022，36（6）：8-11.

         ［12］ 郭志英，李玉锋，徐浩.徐浩教授应用升陷汤治疗慢性心衰临床经验［J］.中国中医急症，2024，33（2）：321-323，372.

         ［13］ 邹晓琪，周狄，陈伶利，等.升陷汤联合隔物灸治疗慢性心力衰竭临床观察［J］.山西中医，2023，39（1）：12-14.

         ［14］ 刘东梅.慢性心力衰竭运用加味升陷汤协同沙库巴曲缬沙坦钠治疗的临床疗效观察［J］.中国医药指南，2025，23（16）：29-31.

         ［15］ 张超，杜宗礼，李正兰，等.加味升陷汤对气虚水停型慢性心力衰竭患者的临床疗效［J］.中成药，2023，45（2）：690-692.

         ［16］ 廉坤，李鑫，胡思远，等.慢性心力衰竭动物模型的研究趋势与热点可视化分析［J］.中药新药与临床药理，2024，35（3）：394-401.

         ［17］ Tan W， Cheng S， Qiu Q， et al. Celastrol exerts antiarrhythmic effects in chronic heart failure via NLRP3/Caspase-1/IL-1β signaling pathway［J］.Biomed Pharmacother， 2024，177：117121.

         ［18］ Yang M， Wu H， Qian H， et al. Linggui Zhugan decoction delays ventricular remodeling in rats with chronic heart failure after myocardial infarction through the Wnt/β-catenin signaling pathway［J］.Phytomedicine， 2023， 120：155026.

         ［19］ Echeverria LE， Bocchi E， Demacq C， et al. Sacubitril/valsartan versus enalapril in chronic Chagas cardiomyopathy with heart failure： baseline characteristics of the PARACHUTE-HF trial［J］.Eur J Heart Fail， 2025，27（12）：2879-2886.

         ［20］ Zhang L， Li Y， Fan CD， et al. Chinese medicinal formula Fu Xin decoction against chronic heart failure by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway［J］.Biomed Pharmacother， 2024，174：116548.

         ［21］ Qin XJ， Gao F， Gao SY， et al. Danggui Buxue decoction activates AMPK/PGC-1α pathway to improve chronic heart failure［J］.J Ethnopharmacol， 2026，355（Pt B）：120680.

         ［22］ Huang C， Qiu S， Fan X， et al. Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats［J］.Biomed Pharmacother， 2021，144：112354.

         ［23］ Jiao G， Wang Y， Song Y， et al. Combination of ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry and network pharmacology to reveal the key effective compounds and mechanism of Shengxian decoction for ameliorating doxorubicin cardiotoxicity［J］.J Sep Sci， 2024，47（9-10）：e2300867.

         ［24］ 周植星，黄芳华.中药注册申报中非临床研究资料常见问题探讨［J］.中草药，2022，53（15）：4905-4914.

         ［25］ 黄芳华，王庆利.古代经典名方中药复方制剂毒理学研究［J］.中国中药杂志，2022，47（23）：6529-6532.

Options
Outlines

/

〈 〉